AJCP / Meeting AbstrActs vWD type I and III. Herein we report two unusual cases of acquired vWD associated with Wilms tumor that suggest the mechanism(s) to be more complex than previously proposed. One patient with Wilms tumor developed acquired vWD with a normal multimer pattern but had a significant reduction in ristocetin cofactor (RCo) activity and borderline low vWF antigen level. Humate-P was administered prebiopsy and every 12 hours subsequently; however, the vWF RCo:antigen ratio was at a nadir of 40% 12 hours post-infusion with the patient enduring no intra-procedural or post-procedural complications. With the lack of other confounding factors to affect metabolism of Humate-P, this suggests an increase in consumption or increase in clearance of the drug. Another patient showed a decrease in high molecular weight multimers with elevated vWF antigen level but low RCo activity with RCo:vWF antigen ratio of 8%, suggesting destruction or consumption of high molecular weight multimers. These two cases illustrate the utility of a comprehensive vWD panel, including multimers, at diagnosis of Wilms tumor and during monitoring of hemostatic treatment. These cases indicate that further studies to understand the mechanism(s) associated with Wilms tumor are warranted.
vWD type I and III. Herein we report two unusual cases of acquired vWD associated with Wilms tumor that suggest the mechanism(s) to be more complex than previously proposed. One patient with Wilms tumor developed acquired vWD with a normal multimer pattern but had a significant reduction in ristocetin cofactor (RCo) activity and borderline low vWF antigen level. Humate-P was administered prebiopsy and every 12 hours subsequently; however, the vWF RCo:antigen ratio was at a nadir of 40% 12 hours post-infusion with the patient enduring no intra-procedural or post-procedural complications. With the lack of other confounding factors to affect metabolism of Humate-P, this suggests an increase in consumption or increase in clearance of the drug. Another patient showed a decrease in high molecular weight multimers with elevated vWF antigen level but low RCo activity with RCo:vWF antigen ratio of 8%, suggesting destruction or consumption of high molecular weight multimers. These two cases illustrate the utility of a comprehensive vWD panel, including multimers, at diagnosis of Wilms tumor and during monitoring of hemostatic treatment. These cases indicate that further studies to understand the mechanism(s) associated with Wilms tumor are warranted. Background: While today's automated chemistry analyzers routinely provide hemolytic, lipemic, and icteric indices in order to assess potential interferences in patient results, the hemolytic index (HI) is by far the best indicator of the degree of contamination of serum/plasma samples with red cell constituents. In vitro hemolysis, often due to poor sample collection and handling, is a well-known source of interference error in the core laboratory. Several analytes, especially potassium and lactate dehydrogenase (LDH), are significantly affected by contamination from red cell constituents. Since the standard of care in our laboratory involves routine testing and reporting of patient samples with an HI of 1+ or greater, a significant technologist effort is required in the decision to validate and release results. Objective: This study presents a novel serial dilution protocol to assess the degree of hemolysis/contamination interference on selected analytes including potassium, LDH, and creatine phosphokinase (CPK) with triglyceride levels included as a negative control.
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Method: Ten lithium heparin whole blood specimens were analyzed for baseline laboratory values on the Rapidpoint 500 analyzer. Two aliquots were made with one frozen at -70°C for 10 minutes to cause complete hemolysis, then thawed and centrifuged for three minutes at 3,100g. Serial dilutions of the supernatant hemolysate up to 1:64 were performed using the unfrozen sample as a diluent, with results of various analytes calculated on the Advia 1800 chemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY). Plasma-free hemoglobin was determined on each sample on the HemoCue analyzer (HemoCue America, Brea, CA). Results: Evaluation of various analytes on all 10 samples obtained by the Advia 1800 showed a significant increase in potassium, LDH, and CPK with an increased HI, with no significant change in the triglyceride level. An example of serial dilution revealed a decreasing potassium level of 9.2 mmol/L, LDH of 1,698 U/L, and CPK of 513 U/L at 4+ hemolysis (no dilution), to 5.3 mmol/L, 187 U/L, and 340 U/L at 1+ hemolysis, respectively (1:32 dilution), compared to a baseline potassium level of 5.2 mmol/L, LDH of 126 U/L, and CPK of 332 U/L with no hemolysis. The HI of 1+ correlates with plasma hemoglobin levels of 50-100 mg/dL, with 18 mg/dL giving an HI of 2+, 350 mg/dL giving an HI of 3+, and 1,390 mg/dL giving an HI of 4+. Conclusion: We conclude that HI values of 1+ on the Advia 1800 are associated with a clinically insignificant 0.1-0.2 mmol/L increase in potassium on all 10 samples. Enzymes, however, showed an increase in all HI levels. Objective: Bone marrow necrosis (BMN) and subsequent embolization of fat and necrotic marrow referred to as fat emboli syndrome (FES) in patients with compound heterozygous sickle cell disorders (SCD) results in multi-organ failure. Patients with BMN/FES present with fatigue, mental status changes, bone pain, fever, anemia, thrombocytopenia, and a leukoerythroblastic picture in the peripheral blood. To date, the etiology and precipitating factors of BMN/FES remain poorly understood. For the past seven years, we have diagnosed 11 patients with BMN/FES in our institution, often because of its similarities with thrombotic thrombocytopenic purpura. Methods: We reviewed the records of patients with confirmed/presumed BMN/FES from April 2010 to February
